Navigation Links
Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008
Date:4/9/2008

he conversion rate was dose-dependent.

The Congressional briefing, sponsored by Congressman James Langevin (D-RI), provides an opportunity for members of Congress and their staff to meet with experts, hear a general overview of spinal cord research and to receive an update on the latest advancements and therapeutic interventions. Dr. Hurtt will be joined by Dr. Damien Pearse of the Miami Project, Dr. Stephen Davies, University of Colorado, Dr. Wise Young, Rutgers University and Dr. Simon Archibald, Integra LifeSciences.

Dr. Hurtt commented, "As we continue to develop CETHRIN with the aim of providing a first-ever therapeutic option for nerve repair to patients with acute spinal cord injury, we are committed to the support of the excellent work of the SCI advocacy groups. These groups reach out to patients, care-givers, professional societies and the general public providing valuable educational, quality of life and often research funding opportunities. We are most pleased to have been invited to the 'Working 2 Walk' Conference and to assist their legislative efforts in the U.S. Congress."

About Working 2 Walk

The third annual "Working 2 Walk" Conference to be held April 13-15, 2008 in Washington, DC is a joint project of Unite 2 Fight Paralysis, a nationwide patient advocacy organization, and the Kennedy Krieger Institute of Baltimore, leaders in rehabilitative strategies that restore function after spinal cord injury. The "Working 2 Walk" Science and Educational Symposium provides a setting for researchers, clinicians and the spinal cord injury community to collaborate on strategies necessary to achieve a cure for paralysis.

About Alseres

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
(Date:8/2/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... to discover and develop antisense therapies for cardiovascular, ... on a broad existing relationship between the two ... therapeutic areas using novel RNA-targeted treatments. It also ... antisense technology to diseases of the kidney. ...
(Date:8/2/2015)... Texas , Aug. 3, 2015  Lexicon ... that the pivotal TELESTAR Phase 3 clinical trial ... oral telotristat etiprate in treating cancer patients with ... the current standard of care. Telotristat etiprate was ... Prize-winning technology, and is the company,s first discovery ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... 7, 2010 Where do you start when trying to ... ), an independent nonprofit that researches the best approaches to ... release of its 5th annual list of Top 10 ... free download with registration, the list features the ...
... Research Group (MRG), the global authority on medical technology ... the US clot management device market.   ... report provides important insight into the device-based treatments ... of medical device manufacturers in this field. The report ...
Cached Medicine Technology:ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 2ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 3Millennium Research Group to Release Their Latest US Clot Management Data 2
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Kill Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can ... back pain in patients. According to the report, the new study showed that harvesting ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health ... overall performance of the company’s Medicare and Federal Employee Programs (FEP) lines of ... deliver better health for members. In this role, Scott is responsible for overseeing ...
Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... (30), a,quadriplegic patient who is dependent on a respirator since ... LASIK procedure performed,by Drs. Jeffrey and Joseph Dello Russo. Eric ... his neck and severing his spinal cord. Since,that day, he ... his body below his upper neck down and is able ...
... Names Kaiser Permanente "Highest in,Member Satisfaction" Among All ... Kaiser Permanente Colorado is the,top-ranked commercial health plan ... a joint ranking by U.S. News & World ... To view the Multimedia News Release, go ...
... survival rates , , FRIDAY, Nov. 7 (HealthDay News) -- ... adults requiring surgery to repair a congenital heart defect, ... occurs when there,s abnormal pre-birth development of the heart ... analyzed a national database to identify 30,250 congenital heart ...
... October 31, 2008 -- Children under the age of three ... behavioral or developmental problems later compared to children who had ... at Columbia University Mailman School of Public Health and the ... children who were born into the New York State Medicaid ...
... Will Be Celebrity Host of Show at Nassau Coliseum, ... today,announced the first of its 2009 Concert Series -- a ... Cancer Research,Foundation., The show will be held on February ... go on sale Monday, November 10th at 10am,through Ticketmaster.com or ...
... National Health Science Summit, DALLAS, Nov. 7 ... today announced Dr. Valentin Fuster, director of,Mount Sinai ... Prize.,The Prize was presented to Dr. Fuster by ... Health Science Summit held on,November 7, 2008 in ...
Cached Medicine News:Health News:Historic LASIK Surgery Performed on Quadriplegic Patient to Preserve his Communication Abilities 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 3Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:General anesthesia for hernia surgery in children and risk of later developmental problems 2Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
Pre-Saturated Sponge Sticks...
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
Medicine Products: